Fibrosis, regeneration, and aging: Playing chess with evolution

Journal of the American Society of Nephrology

Volumn 22, Issue 8, 2011, Pages 1393-1395

  Torres, Vicente E ^a   Leof, Edward B ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; IMATINIB; NILOTINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA;

ACUTE KIDNEY FAILURE; AGING; BONE MARROW SUPPRESSION; CHRONIC KIDNEY DISEASE; CHRONIC MYELOID LEUKEMIA; DIARRHEA; DISEASE COURSE; DRUG MECHANISM; DRUG SAFETY; EDITORIAL; FANCONI RENOTUBULAR SYNDROME; FLUID RETENTION; GLOMERULOSCLEROSIS; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY HYPERTROPHY; LIVER FIBROSIS; LUNG FIBROSIS; MUSCLE CRAMP; NAUSEA; NONHUMAN; PRIORITY JOURNAL; QT PROLONGATION; SIDE EFFECT; TISSUE REGENERATION;

EID: 79960957896     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2011060603     Document Type: Editorial

References (47)

1. Iyoda M, Shibata T, Hirai Y, Kuno Y, Akizawa T: Nilotinib attenuates renal injury and prolongs survival in chronic kidney disease. J Am Soc Nephrol 22: 1486-1496, 2011
2. Rhee CK, Lee SH, Yoon HK, Kim SC, Lee SY, Kwon SS, Kim YK, Kim KH, Kim TJ, Kim JW: Effect of nilotinib on bleomycin-induced acute lung injury and pulmonary fibrosis in mice. Respiration June 9, 2011 [epub ahead of print]
3. Liu Y, Wang Z, Kwong SQ, Lui EL, Friedman SL, Li FR, Lam RW, Zhang GC, Zhang H, Ye T: Inhibition of PDGF, TGF-b, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib. J Hepatol January 18, 2011 [epub ahead of print]
4. Shaker ME, Salem HA, Shiha GE, Ibrahim TM: Nilotinib counteracts thioacetamide-induced hepatic oxidative stress and attenuates liver fibrosis progression. Fundam Clin Pharmacol 25: 248-257, 2011
5. Jabbour E, Cortes J, Kantarjian H: Long-term outcomes in the secondline treatment of chronic myeloid leukemia: A review of tyrosine kinase inhibitors. Cancer 117: 897-906, 2011
6. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Huguet F, Boque C, Chuah C, Bleickardt E, Bradley-Garelik MB, Zhu C, Szatrowski T, Shapiro D, Baccarani M: Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362: 2260-2270, 2010
7. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM: Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362: 2251-2259, 2010
8. Manley PW, Stiefl N, Cowan-Jacob SW, Kaufman S, Mestan J, Wartmann M, Wiesmann M, Woodman R, Gallagher N: Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. Bioorg Med Chem 18: 6977-6986, 2010
9. Steinberg M: Dasatinib: A tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Ther 29: 2289-2308, 2007
10. Ferguson MW, O'Kane S: Scar-free healing: From embryonic mechanisms to adult therapeutic intervention. Phi Trans R Soc Lond B Biol Sci 359: 839-850, 2004 (Pubitemid 38673751)
11. Harty M, Neff AW, King MW, Mescher AL: Regeneration or scarring: An immunologic perspective. Dev Dyn 226: 268-279, 2003 (Pubitemid 36158171)
12. Floege J, Eitner F, Alpers CE: A new look at platelet-derived growth factor in renal disease. J Am Soc Nephrol 19: 12-23, 2008
13. Ostendorf T, Eitner F, Floege J: The PDGF family in renal fibrosis. Pediatr Nephrol May 21, 2011 [epub ahead of print]
14. Eitner F, Bucher E, van Roeyen C, Kunter U, Rong S, Seikrit C, Villa L, Boor P, Fredriksson L, Backstrom G, Eriksson U, Ostman A, Floege J, Ostendorf T: PDGF-C is a proinflammatory cytokine that mediates renal interstitial fibrosis. J Am Soc Nephrol 19: 281-289, 2008 (Pubitemid 351240650)
15. Ludewig D, Kosmehl H, Sommer M, Bohmer FD, Stein G: PDGF receptor kinase blocker AG1295 attenuates interstitial fibrosis in rat kidney after unilateral obstruction. Cell Tissue Res 299: 97-103, 2000 (Pubitemid 30028726)
16. Wang S, Wilkes MC, Leof EB, Hirschberg R: Noncanonical TGF-beta pathways, mTORC1 and Abl, in renal interstitial fibrogenesis. Am J Physiol Renal Physiol 298: F142-F149, 2010
17. Hong M, Wilkes MC, Penheiter SG, Gupta SK, Edens M, Leof EB: Non-Smad transforming growth factor-beta signaling regulated by focal adhesion kinase binding the p85 subunit of phosphatidylinositol 3-kinase. J Biol Chem 286: 17841-17850, 2011
18. Torres VE, Boletta A, Chapman A, Gattone V, Pei Y, Qian Q, Wallace DP, Weimbs T, Wuthrich RP: Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases. Clin J Am Soc Nephrol 5: 1312-1329, 2010
19. Chitu V, Stanley ER: Colony-stimulating factor-1 in immunity and inflammation. Cur Opin Immunol 18: 39-48, 2006 (Pubitemid 43049646)
20. Menke J, Iwata Y, Rabacal WA, Basu R, Yeung YG, Humphreys BD, Wada T, Schwarting A, Stanley ER, Kelley VR: CSF-1 signals directly to renal tubular epithelial cells to mediate repair in mice. J Clin Invest 119: 2330-2342, 2009
21. Stokman G, Stroo I, Claessen N, Teske GJ, Weening JJ, Leemans JC, Florquin S: Discoidin domain receptor 1 is a major mediator of inflammation and fibrosis in obstructive nephropathy. Am J Pathol 179: 83-91, 2011
22. Avivi-Green C, Singal M, Vogel WF: Discoidin domain receptor 1-deficient mice are resistant to bleomycin-induced lung fibrosis. Am J Respir Crit Care Med 174: 420-427, 2006 (Pubitemid 44223123)
23. Gross O, Girgert R, Beirowski B, Kretzler M, Kang HG, Kruegel J, Miosge N, Busse AC, Segerer S, Vogel WF, Muller GA, Weber M: Loss of collagen-receptor DDR1 delays renal fibrosis in hereditary type IV collagen disease. Matrix Biol 29: 346-356, 2010
24. Stokman G, Stroo I, Claessen N, Teske GJ, Weening JJ, Leemans JC, Florquin S: Stem cell factor expression after renal ischemia promotes tubular epithelial survival. PloS One 5: e14386, 2010
25. Jones SE, Kelly DJ, Cox AJ, Zhang Y, Gow RM, Gilbert RE: Mast cell infiltration and chemokine expression in progressive renal disease. Kidney Int 64: 906-913, 2003 (Pubitemid 37013826)
26. Boor P, Ostendorf T, Floege J: Renal fibrosis: Novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol 6: 643-656, 2010
27. Zeisberg M, Neilson EG: Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol 21: 1819-1834, 2010
28. Zeisberg M, Duffield JS: Resolved: EMT produces fibroblasts in the kidney. J Am Soc Nephrol 21: 1247-1253, 2010
29. Quaggin SE, Kapus A: Scar wars: Mapping the fate of epithelialmesenchymal-myofibroblast transition. Kidney Int 80: 41-50, 2011
30. Kida Y, Duffield JS: Pivotal role of pericytes in kidney fibrosis. Clin Exp Pharmacol Physiol 38: 417-423, 2011
31. Corselli M, Chen CW, Crisan M, Lazzari L, Peault B: Perivascular ancestors of adult multipotent stem cells. Arterioscler Thromb Vasc Biol 30: 1104-1109, 2010
32. Ferguson MW, Duncan J, Bond J, Bush J, Durani P, So K, Taylor L, Chantrey J, Mason T, James G, Laverty H, Occleston NL, Sattar A, Ludlow A, O'Kane S: Prophylactic administration of avotermin for improvement of skin scarring: Three double-blind, placebo-controlled, phase I/II studies. Lancet 373: 1264-1274, 2009
33. Savikko J, Rintala JM, Rintala SE, Koskinen PK, von Willebrand E: Early short-term imatinib treatment is sufficient to prevent the development of chronic allograft nephropathy. Nephrol Dial Transplant February 1, 2011 [epub ahead of print]
34. Iwamoto N, Distler JH, Distler O: Tyrosine kinase inhibitors in the treatment of systemic sclerosis: From animal models to clinical trials. Curr Rheumatol Rep 13: 21-27, 2011
35. Elmholdt TR, Pedersen M, Jørgensen B, Ramsing M, Olesen AB: Positive effect of low-dose imatinib mesylate in a patient with nephrogenic systemic fibrosis. Acta Derm Venereol 91: 478-479, 2011
36. Magro L, Mohty M, Catteau B, Coiteux V, Chevallier P, Terriou L, Jouet JP, Yakoub-Agha I: Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood 114: 719-722, 2009
37. Olivieri A, Locatelli F, Zecca M, Sanna A, Cimminiello M, Raimondi R, Gini G, Mordini N, Balduzzi A, Leoni P, Gabrielli A, Bacigalupo A: Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood 114: 709-718, 2009
38. Spiera RF, Gordon JK, Mersten JN, Magro CM, Mehta M, Wildman HF, Kloiber S, Kirou KA, Lyman S, Crow MK: Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: Results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis 70: 1003-1009, 2011
39. Daniels CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR: Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med 181: 604-610, 2010
40. Pinilla-Ibarz J, Cortes J, Mauro MJ: Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications. Cancer 117: 688-697, 2011
41. Doggrell SA, Christensen AM: Are there better Bcr-Abl kinase inhibitors for chronic myeloid leukaemia than imatinib? Evaluation of Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-9,
42. and Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-70.
43. Expert Opin Pharmacother 12: 157-163, 2011
44. Francois H, Coppo P, Hayman JP, Fouqueray B, Mougenot B, Ronco P: Partial Fanconi syndrome induced by imatinib therapy: A novel cause of urinary phosphate loss. Am J Kidney Dis 51: 298-301, 2008
45. Gafter-Gvili A, Ram R, Gafter U, Shpilberg O, Raanani P: Renal failure associated with tyrosine kinase inhibitors: Case report and review of the literature. Leuk Res 34: 123-127, 2010
46. Holstein SA, Stokes JB, Hohl RJ: Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia. Leuk Res 33: 344-347, 2009
47. Marcolino MS, Boersma E, Clementino NC, Macedo AV, Marx-Neto AD, Silva MH, van Gelder T, Akkerhuis KM, Ribeiro AL: Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients. Ann Oncol May 26, 2011 [epub ahead of print]